My watch list  

3,557 Current news from the ressort products


You can refine your search further. Select from the filter options on the left to narrow down your results.

Millennium and Abbott Initiate Phase I Trials of their First Genomically-Derived Drug Target for Obesity


CAMBRIDGE, Mass., and ABBOTT PARK, Ill., November 27, 2001 - Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Abbott Laboratories, (NYSE: ABT) today announced the initiation of a Phase I clinical trial of MLN4760. This represents the first molecule directed against a genomically-derived target ...


Monsanto Company Files Patent Infringement Suit Against Generic Glyphosate Importer/Seller


ST. LOUIS, November 13, 2001 - Monsanto Company, the inventor of Roundup® glyphosate herbicide technology, filed suit against Chemical Products Technologies, LLC (CPT), Zetachem USA Inc. and Zetachem PTY LTD. for infringement of three Monsanto patents covering the commercial production of ...


Monsanto Makes Improvements to Website


ST. LOUIS (Nov. 12, 2001) - Monsanto Company recently launched a new and improved FarmSource web site tailored to meet the needs of its grower, dealer, retailer and distributor customers. The site provides Monsanto customers with new user-friendly drop-down menus and faster access to information ...


FDA Approves Viread For HIV-1 Infection


The Food and Drug Administration has approved Viread (tenofovir disoproxil fumarate), a new antiviral drug indicated for treatment of HIV-1 infection in combination with other antiretroviral medicines. Tenofovir disoproxil fumarate is the first nucleotide analog approved for HIV-1 treatment. ...


Novartis submits supplemental NDA with US FDA for Glivec® for treatment of certain GI tumors


Novartis announced today that it has submitted a supplementary New Drug Application (sNDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for its novel drug Glivec® (imatinib)* for the treatment of patients with unresectable (inoperable) and/or metastatic malignant ...


DoubleTwist Licenses Prophecy Database and Tools Suite to GPC Biotech


OAKLAND, Calif.--Oct. 16, 2001--DoubleTwist, Inc. today announced that GPC Biotech has licensed its Prophecy(TM) database and tools suite. DoubleTwist recently announced the release of its third generation of the product, which includes an assembled genome and integration of more than 35 ...


Genzyme To Launch Thyrogen® in Europe


Genzyme General, a division of Genzyme Corp., announced October 15 that it will begin marketing Thyrogen® (thyrotropin alfa for injection) in Europe this month. Thyrogen is a recombinant human thyroid stimulating hormone indicated for use in the management of patients being followed up for the ...


Page 356 From 356
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE